231 related articles for article (PubMed ID: 30264681)
21. Formulation and evaluation of injectable in situ forming microparticles for sustained delivery of lornoxicam.
Yehia SA; Abdel-Halim SA; Aziz MY
Drug Dev Ind Pharm; 2017 Feb; 43(2):319-328. PubMed ID: 27671477
[TBL] [Abstract][Full Text] [Related]
22. In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor.
Kapoor DN; Katare OP; Dhawan S
Int J Pharm; 2012 Apr; 426(1-2):132-143. PubMed ID: 22266533
[TBL] [Abstract][Full Text] [Related]
23. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
Li F; Song S; Guo Y; Zhao Q; Zhang X; Pan W; Yang X
Drug Deliv; 2015; 22(4):487-98. PubMed ID: 24524289
[TBL] [Abstract][Full Text] [Related]
24. Formulation of Niosomal Gel for Enhanced Transdermal Lornoxicam Delivery: In-Vitro and In-Vivo Evaluation.
El-Ridy MS; Yehia SA; Mohsen AM; El-Awdan SA; Darwish AB
Curr Drug Deliv; 2018; 15(1):122-133. PubMed ID: 28240177
[TBL] [Abstract][Full Text] [Related]
25. Characterization of two polymorphs of lornoxicam.
Zhang J; Tan X; Gao J; Fan W; Gao Y; Qian S
J Pharm Pharmacol; 2013 Jan; 65(1):44-52. PubMed ID: 23215687
[TBL] [Abstract][Full Text] [Related]
26. Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation.
Ranjan OP; Shavi GV; Nayak UY; Arumugam K; Averineni RK; Meka SR; Sureshwar P
Arch Pharm Res; 2011 Nov; 34(11):1919-29. PubMed ID: 22139691
[TBL] [Abstract][Full Text] [Related]
27. Injectable PLGA Adefovir microspheres; the way for long term therapy of chronic hepatitis-B.
Ayoub MM; Elantouny NG; El-Nahas HM; Ghazy FES
Eur J Pharm Sci; 2018 Jun; 118():24-31. PubMed ID: 29555501
[TBL] [Abstract][Full Text] [Related]
28. Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins.
Desai KG; Olsen KF; Mallery SR; Stoner GD; Schwendeman SP
Pharm Res; 2010 Apr; 27(4):628-43. PubMed ID: 20148292
[TBL] [Abstract][Full Text] [Related]
29. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.
Kelley RA; Ghaffari A; Wang Y; Choi S; Taylor JR; Hartman RR; Kompella UB
J Ocul Pharmacol Ther; 2020 Jun; 36(5):290-297. PubMed ID: 32330403
[No Abstract] [Full Text] [Related]
30. Formulation and evaluation of proniosomes containing lornoxicam.
Madan JR; Ghuge NP; Dua K
Drug Deliv Transl Res; 2016 Oct; 6(5):511-8. PubMed ID: 27255375
[TBL] [Abstract][Full Text] [Related]
31. Formulation Optimization and In-vitro and In-vivo Evaluation of Lornoxicam Ethosomal Gels with Penetration Enhancers.
Li K; Gao S; Tian B; Shi Y; Lv Q; Han J
Curr Drug Deliv; 2018; 15(3):424-435. PubMed ID: 29219057
[TBL] [Abstract][Full Text] [Related]
32. In Vitro and In Vivo Evaluation of Lidocaine Hydrochloride-loaded Injectable Poly(Lactic-co-glycolic Acid) Implants.
Li Y; Shi X
Curr Drug Deliv; 2018; 15(10):1411-1416. PubMed ID: 30207229
[TBL] [Abstract][Full Text] [Related]
33. Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation.
Shahzad Y; Khan Q; Hussain T; Shah SN
Int J Biol Macromol; 2013 Oct; 61():26-32. PubMed ID: 23827761
[TBL] [Abstract][Full Text] [Related]
34. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
[TBL] [Abstract][Full Text] [Related]
35. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188.
Newa M; Bhandari KH; Li DX; Kwon TH; Kim JA; Yoo BK; Woo JS; Lyoo WS; Yong CS; Choi HG
Int J Pharm; 2007 Oct; 343(1-2):228-37. PubMed ID: 17597315
[TBL] [Abstract][Full Text] [Related]
36. Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis.
Hadi MA; Rao NG; Rao AS
Pak J Pharm Sci; 2015 Jan; 28(1):185-93. PubMed ID: 25553695
[TBL] [Abstract][Full Text] [Related]
37. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
38. Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers.
Radhofer-Welte S; Dittrich P; Simin M; Branebjerg PE
Clin Drug Investig; 2008; 28(6):345-51. PubMed ID: 18479176
[TBL] [Abstract][Full Text] [Related]
39. Temperature-dependent in Situ Gel of Clotrimazole: an Experimental Study.
Patel VP; Damasiya HM; Kapupara P; Ashara KC
Folia Med (Plovdiv); 2019 Jun; 61(2):266-276. PubMed ID: 31301667
[TBL] [Abstract][Full Text] [Related]
40. Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination.
Hamza Yel-S; Aburahma MH
AAPS PharmSciTech; 2009; 10(4):1357-67. PubMed ID: 19921543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
